Chongqing Zhifei Bio Products (300122) - Net Assets

Latest as of March 2026: CN¥15.71 Billion CNY ≈ $2.30 Billion USD

Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has net assets worth CN¥15.71 Billion CNY (≈ $2.30 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥29.09 Billion ≈ $4.26 Billion USD) and total liabilities (CN¥13.38 Billion ≈ $1.96 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 300122 total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥15.71 Billion
% of Total Assets	54.01%
Annual Growth Rate	28.05%
5-Year Change	-8.78%
10-Year Change	538.81%
Growth Volatility	87.03

Chongqing Zhifei Bio Products - Net Assets Trend (2007–2025)

This chart illustrates how Chongqing Zhifei Bio Products's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Chongqing Zhifei Bio Products to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Chongqing Zhifei Bio Products (2007–2025)

The table below shows the annual net assets of Chongqing Zhifei Bio Products from 2007 to 2025. For live valuation and market cap data, see 300122 market cap.

Year	Net Assets	Change
2025-12-31	CN¥16.11 Billion ≈ $2.36 Billion	-47.76%
2024-12-31	CN¥30.83 Billion ≈ $4.51 Billion	-2.14%
2023-12-31	CN¥31.51 Billion ≈ $4.61 Billion	+30.00%
2022-12-31	CN¥24.24 Billion ≈ $3.55 Billion	+37.26%
2021-12-31	CN¥17.66 Billion ≈ $2.58 Billion	+114.06%
2020-12-31	CN¥8.25 Billion ≈ $1.21 Billion	+43.52%
2019-12-31	CN¥5.75 Billion ≈ $841.02 Million	+37.47%
2018-12-31	CN¥4.18 Billion ≈ $611.80 Million	+42.33%
2017-12-31	CN¥2.94 Billion ≈ $429.85 Million	+16.51%
2016-12-31	CN¥2.52 Billion ≈ $368.94 Million	+2.11%
2015-12-31	CN¥2.47 Billion ≈ $361.33 Million	+0.47%
2014-12-31	CN¥2.46 Billion ≈ $359.64 Million	+2.87%
2013-12-31	CN¥2.39 Billion ≈ $349.62 Million	+0.69%
2012-12-31	CN¥2.37 Billion ≈ $347.24 Million	+5.09%
2011-12-31	CN¥2.26 Billion ≈ $330.43 Million	+5.43%
2010-12-31	CN¥2.14 Billion ≈ $313.40 Million	+374.15%
2009-12-31	CN¥451.69 Million ≈ $66.10 Million	+69.14%
2008-12-31	CN¥267.06 Million ≈ $39.08 Million	+42.03%
2007-12-31	CN¥188.03 Million ≈ $27.52 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Chongqing Zhifei Bio Products's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7359.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥12.34 Billion	77.92%
Other Components	CN¥3.50 Billion	22.08%
Total Equity	CN¥15.84 Billion	100.00%

Chongqing Zhifei Bio Products Competitors by Market Cap

The table below lists competitors of Chongqing Zhifei Bio Products ranked by their market capitalization.

Company	Market Cap
Reinet Investments SCA JSE:RNI	$4.52 Billion
Fulton Financial Corporation NASDAQ:FULT	$4.52 Billion
KURITA WTR IND.UNSP.ADR 2 F:KWI0	$4.52 Billion
Kulicke and Soffa Industries Inc F:KU1	$4.53 Billion
SiteOne Landscape Supply Inc NYSE:SITE	$4.51 Billion
Franklin Electric Co Inc NASDAQ:FELE	$4.51 Billion
BURBERRY GROUP ADR/ F:BB2A	$4.51 Billion
Algonquin Power & Utilities Corp TO:AQN	$4.51 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Chongqing Zhifei Bio Products's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 30,830,739,408 to 15,839,778,819, a change of -14,990,960,589 (-48.6%).
Net loss of 14,723,152,852 reduced equity.
Dividend payments of 344,806,187 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-14.72 Billion	-92.95%
Dividends Paid	CN¥344.81 Million	-2.18%
Other Changes	CN¥77.00 Million	+0.49%
Total Change	CN¥-	-48.62%

Book Value vs Market Value Analysis

This analysis compares Chongqing Zhifei Bio Products's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.95x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 152.95x to 1.95x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	CN¥0.08	CN¥12.90	x
2008-12-31	CN¥0.12	CN¥12.90	x
2009-12-31	CN¥0.20	CN¥12.90	x
2010-12-31	CN¥1.53	CN¥12.90	x
2011-12-31	CN¥1.43	CN¥12.90	x
2012-12-31	CN¥1.48	CN¥12.90	x
2013-12-31	CN¥1.48	CN¥12.90	x
2014-12-31	CN¥1.52	CN¥12.90	x
2015-12-31	CN¥1.55	CN¥12.90	x
2016-12-31	CN¥1.62	CN¥12.90	x
2017-12-31	CN¥1.84	CN¥12.90	x
2018-12-31	CN¥2.61	CN¥12.90	x
2019-12-31	CN¥3.59	CN¥12.90	x
2020-12-31	CN¥5.16	CN¥12.90	x
2021-12-31	CN¥11.04	CN¥12.90	x
2022-12-31	CN¥10.10	CN¥12.90	x
2023-12-31	CN¥13.13	CN¥12.90	x
2024-12-31	CN¥12.87	CN¥12.90	x
2025-12-31	CN¥6.62	CN¥12.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Chongqing Zhifei Bio Products utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -92.95%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -164.35%
• Asset Turnover: 0.28x
• Equity Multiplier: 2.00x
Recent ROE (-92.95%) is below the historical average (21.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	80.84%	30.87%	1.48x	1.77x	CN¥133.21 Million
2008	71.16%	32.19%	1.51x	1.46x	CN¥163.35 Million
2009	51.27%	38.34%	1.17x	1.15x	CN¥186.42 Million
2010	11.99%	34.83%	0.33x	1.03x	CN¥42.62 Million
2011	8.70%	31.23%	0.26x	1.06x	CN¥-29.42 Million
2012	9.06%	28.28%	0.30x	1.06x	CN¥-22.25 Million
2013	5.46%	16.71%	0.30x	1.08x	CN¥-108.58 Million
2014	6.02%	18.48%	0.30x	1.10x	CN¥-97.77 Million
2015	7.99%	27.70%	0.27x	1.09x	CN¥-49.52 Million
2016	1.29%	7.29%	0.16x	1.07x	CN¥-219.61 Million
2017	14.72%	32.20%	0.33x	1.40x	CN¥138.52 Million
2018	34.71%	27.76%	0.77x	1.63x	CN¥1.03 Billion
2019	41.17%	22.35%	0.97x	1.90x	CN¥1.79 Billion
2020	40.02%	21.73%	1.00x	1.85x	CN¥2.48 Billion
2021	57.82%	33.30%	1.02x	1.70x	CN¥8.44 Billion
2022	31.11%	19.70%	1.01x	1.57x	CN¥5.12 Billion
2023	25.61%	15.25%	1.05x	1.59x	CN¥4.92 Billion
2024	6.55%	7.74%	0.52x	1.62x	CN¥-1.06 Billion
2025	-92.95%	-164.35%	0.28x	2.00x	CN¥-16.31 Billion

Industry Comparison

This section compares Chongqing Zhifei Bio Products's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $2,555,577,319
Average return on equity (ROE) among peers: -11.77%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Chongqing Zhifei Bio Products (300122)	CN¥15.71 Billion	80.84%	0.85x	$4.52 Billion
Shenzhen CAU Technology Co Ltd (000004)	$72.91 Million	-180.40%	3.27x	$9.88 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403)	$351.68 Million	19.98%	2.38x	$1.33 Billion
Nanhua Bio Medicine Co Ltd (000504)	$110.32 Million	-17.34%	4.98x	$385.38 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518)	$611.10 Million	0.73%	0.66x	$537.84 Million
Chengzhi Shareholding Co Ltd (000990)	$16.07 Billion	5.03%	0.31x	$1.64 Billion
Hualan Biological EngineeringInc (002007)	$550.80 Million	9.54%	0.27x	$3.53 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030)	$1.94 Billion	5.22%	0.57x	$1.05 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252)	$231.70 Million	22.12%	0.44x	$4.99 Billion
Baolingbao Biology Co Ltd (002286)	$1.51 Billion	3.27%	0.28x	$418.78 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287)	$4.11 Billion	14.16%	0.65x	$1.76 Billion

About Chongqing Zhifei Bio Products

SHE:300122 China Biotechnology

Market Cap

$4.52 Billion

CN¥30.88 Billion CNY

Market Cap Rank

#3783 Global

#534 in China

Share Price

CN¥12.90

Change (1 day)

+1.10%

52-Week Range

CN¥11.37 - CN¥25.06

All Time High

CN¥11976.62